Oct 31 (Reuters) - Contract research firm IQVIA (IQV.N), opens new tab lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical ...

IQVIA Holdings Inc. IQV has had an impressive run over the past three months. The stock has gained 9.3%, outperforming the 3.9% rise of the industry it belongs to and the Zacks S&P 500 composite ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31 ...

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides advanced analytics, technology solutions, and clinical research services to the life sciences industry. It operates through ...

In a report released yesterday, Charles Rhyee from TD Cowen maintained a Buy rating on IQVIA Holdings (IQV – Research Report), with a price target of $255.00. Charles Rhyee has given his Buy ...

Analyst Michael Ryskin from Bank of America Securities reiterated a Buy rating on IQVIA Holdings (IQV – Research Report) and decreased the price target to $255.00 from $260.00. Michael Ryskin ...

IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.49 per share a year ago.

Fintel reports that on October 14, 2024, Redburn Atlantic initiated coverage of IQVIA Holdings (NYSE:IQV) with a Buy recommendation. Analyst Price Forecast Suggests 20.08% Upside As of September ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to ...